Further evaluation of other hub genes (PIK3CAwt, NF1wt, ARID1wt, MYCNOSwt, and MUTYHwt) in BRCA1/2wt, HRP cancer patients as potential biomarkers for Vigil treatment, and possibly indicators of novel added therapeutic management, may be fruitful. Here, BRCA1 is linked to cancer.